<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2811222946
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2013
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PENTASA 1GM PROLONGED RELEASE GRANULES
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MESALAZINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        g
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Prolonged-release granules
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Sachet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        166.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="FERRING" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            FERRING
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            FERRING
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A07EC02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>PENTASA&reg; 1g Sachets is used for the treatment of mild to moderate attacks of ulcerative colitis and to help maintain freedom from further attacks. Ulcerative colitis is an inflammatory bowel disease in which the lining of the intestine becomes<br />inflamed and develops many tiny breaks in its surface (ulcers) which may bleed.<br />PENTASA&reg; 1g Sachets contains granules that slowly release the active ingredient (mesalazine). This helps reduce the inflammation and the painful symptoms.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take PENTASA&reg; 1g Sachets<br />- if you are allergic (hypersensitive) to mesalazine or any of the other ingredients of this medicine (see Section 6);<br />- if you are allergic to other salicylates e.g. acetylsalicylic acid;<br />- if you have severe liver and/or kidney problems.</p><p><strong>Warnings and Precautions</strong><br />Talk to your doctor or pharmacist before taking PENTASA&reg; 1g Sachets:<br />- if you are allergic to sulphasalazine (risk of allergy to salicylates);<br />- if you currently have or have previously had liver and/or kidney disease;<br />- if you have a medical condition that can make you prone to bleeding;<br />- if you have an active peptic ulcer (stomach ulcer or duodenal ulcer);<br />- if you are on medication that may affect kidney function e.g. non-steroidal anti-inflammatory drugs (NSAIDs) such as acetylsalicylic acid;<br />- if you have lung problems, in particular asthma;<br />- if you suddenly develop abdominal cramps, abdominal pain, fever, severe headache and rash. In such circumstances you should stop taking PENTASA&reg; immediately.<br />While you are on treatment with this medicine, your doctor will normally arrange blood tests to check your kidney function especially at the beginning of treatment.<br /><strong>Other medicines and PENTASA&reg; 1g Sachets</strong><br />Tell your doctor or pharmacist if you are using, or have recently used, any other medicines, including medicines obtained without a prescription. This is especially important if you are taking any of the following:<br />- azathioprine (used after transplantations or to treat auto-immune diseases);<br />- 6-mercaptopurine or thioguanine (chemotherapy, used to treat leukaemia);<br />- Certain agents that inhibit blood clotting (medicines for thrombosis or to thin your blood).<br /><strong>Pregnancy, breast-feeding and fertility</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.<br />There is limited experience with the use of mesalazine during pregnancy and breast-feeding. Blood disorders have been reported in newborns of mothers being treated with this medicine.<br />The newborn may develop allergic reactions after breast-feeding, e.g. diarrhoea. If the newborn develops diarrhoea, breast-feeding should be discontinued.<br /><strong>Driving and using machines</strong><br />This medicine is not known to affect the ability to drive and/or use machines.<br />Note: The risk of colorectal cancer (CRC) is slightly increased in ulcerative colitis, Observed effects of mesalazine in experimental models and patient biopsies support the role of mesalazine in prevention of colitis-associated CRC, with<br />downregulation of both inflammation dependent and non-inflammation dependent signaling pathways involved in the development of colitis-associated CRC</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take PENTASA&reg; 1g Sachets exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.<br /><u>Adults:</u><br /><strong>To treat an attack of ulcerative colitis, your doctor will normally prescribe a dose of up to 4 g mesalazine (1-4 sachets) either once daily or divided into single doses.<br />To help maintain freedom from further attacks, your doctor will usually prescribe 2 g mesalazine a day administered as one sachet of PENTASA&reg; Xtend 2g Sachets or two sachets of PENTASA&reg; 1g Sachets Prolonged Release Granules.</strong><br /><u>Use in children and adolescents<br />Children from the age of 6 years:s</u><br />The dosing for children is determined by your doctor and depends on the body weight of the child. It is generally recommended that half the adult dose may be given to children up to a body weight of 40 kg; and the normal adult dose to<br />those above 40 kg.<br />You should take the granules orally (by mouth), immediately after opening the sachet, as described below. Do not chew the granules.<br />1. Open the foil sachet<br />2. Empty the contents of the sachet onto the tongue<br />3. Wash the granules down immediately with some water or orange juice ensuring that none remain in the mouth.<br /><strong>If you take more PENTASA&reg; 1g Sachets than you should</strong><br />In the event of overdose, contact your doctor or nearest casualty department immediately.<br /><strong>If you forget to take PENTASA&reg; 1g Sachets</strong><br />If you have forgotten to take a dose, then take it as soon as you remember, and then take the next dose at the usual time. Do not take a double dose to make up for a forgotten dose.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines this medicine can cause side effects, although not everybody gets them.<br />There have been very few reports of a severe allergic reaction (including severe skin erosions that may affect the skin as the protective barrier of the body). The allergic reaction might lead to swelling of the face and neck and/or difficulty in<br />breathing or swallowing (Quincke&acute;s oedema). If this happens contact your doctor or nearest casualty department immediately.<br /><strong>The following common side effects</strong> may affect up to 1 of 10 patients treated:<br />Diarrhoea; abdominal pain; nausea; vomiting; headache; rash; flatulence (passing wind).<br /><strong>The following rare side effects</strong> may affect up to 1 of 1,000 patients treated:<br />Inflammation of some areas of the heart (myocarditis and pericarditis) which can cause shortness of breath and chest pain or palpitations (rapid or irregular heart beats); inflammation of the pancreas (pancreatitis); symptoms include back<br />and/or stomach pain; increased amylase (enzyme that helps digest carbohydrates); dizziness; increased sensitivity of your skin to sun and ultraviolet light (photosensitivity).<br /><strong>The following very rare side effects </strong>may affect up to 1 of 10,000 patients:<br />Anaemia and other blood disorders (decrease in the numbers of certain blood cells, which can cause unexplained bleeding, bruising, fever or sore throat); liver disorders (symptoms include jaundice (yellowing of the skin and/ or eyes) and/or<br />pale bowel motions); kidney disorders (symptoms include blood in the urine, and/or oedema (swelling due to build up of fluid)); peripheral neuropathy (a condition affecting the nerves of the hands and feet symptoms include tingling and<br />numbness); allergic and fibrotic lung reactions, inflammation of the lining of the lungs or lung scarring (symptoms include coughing, bronchial cramps (bronchospasm), chest discomfort or pain in breathing, breathing difficulties, bloody<br />and/or excessive phlegm); pancolitis (a kind of inflammatory bowel disorder (IBD) that affects the entire internal lining of the large bowel); hair loss (this is reversible); muscle or joint pain; inflammation which can affect different parts<br />of the body such as joints, skin, kidneys, heart etc. (symptoms include painful joints, fatigue, fever, abnormal or unexplained bleeding (e.g. nose bleeds), bruising, purple discoloration of the skin (including severe skin erosions and<br />severe blistering that may affect the skin as the protective barrier of the body)); accumulation of fluid around the heart (pericardial effusion) which can cause chest pain or pressure; change in urine colour; semen with a low<br />concentration of sperm (oligospermia) (this is reversible); severe diarrhoea and abdominal pain because of an allergic reaction to this medicine within the bowel; allergic reactions and fever may occasionally occur.<br />There have been very few reports of benign intracranial hypertension (build up of fluid around the brain) in adolescents. Symptoms include headache, nausea, vomiting, and/or visual or hearing disturbances</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and foil sachet. The expiry date refers to the last day of that month.<br />Store at room temperature (below 25&deg; C) in the original packaging away from light.<br />Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u>The active ingredient</u> is mesalazine: Each sachet PENTASA&reg; 1g Sachets Prolonged Release Granules contains mesalazine 2g.<br /><u>The other ingredients are</u>: ethylcellulose, povidone</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This medicine contains prolonged release granules. The granules are white-grey to pale white-brown. PENTASA® 1g Sachets is available in aluminium foil sachets in packs of 60 sachets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufacturer</strong><br />Ferring International Center SA,<br />Chemin de la Vergognauzas 50,<br />1162 St-Prex,<br />Switzerland.<br /><strong>Marketing Authorization Holder</strong><br />Ferring GmbH,<br />Wittland 11,<br />D-24109 Kiel,<br />Germany.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                June 2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يستخدم بنتاسا&reg;&nbsp;١غم أكياس من&nbsp;أجل علاج النوبات البسيطة الى المتوسطة من التهاب القولون التقرحي وللمساعدة في&nbsp;الوقاية من حدوث المزيد من النوبات. التهاب القولون التقرحي هو داء الأمعاء الالتهابي الذي تكون به بطانة الأمعاء ملتهبة، وقد يتطور إلى ثقوب صغيرة على سطحها )قرحات( التي من الممكن أن تنزف.</p><p>يحتوي بنتاسا&nbsp;&reg;&nbsp;١ غم أكياس على حبيبات تطلق المادة الفعالة )ميسالازين( ببطء. هذا يساعد على تقليل الالتهاب&nbsp;والأعراض المؤلمة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تأخذ بنتاسا&nbsp;&reg; ١ غم أكياس:</strong></p><p>- إذا كنت تعاني من حساسية للميسالازين، أو إلى أي من المكونات الأخرى من هذا الدواء؛<br />- إذا كنت تعاني من حساسية للساليسيلات الأخرى مثل حمض الأسيتيل ساليسيليك؛<br />- إذا كان لديك مشاكل شديدة في الكبد و/ أو الكلى.</p><p><strong>التحذيرات والاحتياطات:</strong><br />تحدث إلى طبيبك أو الصيدلي قبل أخذ بنتاسا&nbsp;&reg;&nbsp;١ غم أكياس<br />- إذا كنت تعاني من حساسية للسلفاسالازين )يوجد خطر الإصابة بحساسية الساليسيلات(؛<br />- إذا كان لديك حالياً أو سبق لك أن أصبت بمرض في الكبد و / أو في الكلى؛<br />- إذا كان لديك حالة طبية يمكن أن تجعلك عرضة للنزيف؛<br />- إذا كان لديك قرحة نشطة في المعدة أو الاثني عشر؛<br />- إذا كنت تعالج بدواء قد يؤثر على وظائف الكلى على سبيل المثال الأدوية المضادة للالتهابات غير الستيرويدية مثل<br />حمض الأسيتيل ساليسيليك؛<br />- إذا كان لديك أمراض بالرئة، خاصة الربو؛<br />- إذا أصبت فجأة بتشنجات في البطن، آلام في البطن، الحمى، الصداع الشديد أو الطفح الجلدي. في مثل هذه الظروف يجب أن تتوقف فوراً عن تناول بنتاسا &reg;</p><p>أثناء علاجك بهذا الدواء، سوف يرتب لك طبيبك عادة فحوصات للدم لفحص وظائف الكلى وخاصة في بداية العلاج.</p><p><strong>الأدوية الأخرى وبنتاسا&nbsp;&reg; ١ غم أكياس:</strong></p><p>أخبر طبيبك أو الصيدلي إذا كنت تستخدم، أو استخدمت مؤخراً أو قد تستخدم أي أدوية أخرى بما في ذلك أي أدوية<br />تحصل عليها بدون وصفة طبية. هذا أمر مهم خاصة إذا كنت تأخذ أي من الأدوية التالية:<br />- آزاثيوبرين (يستخدم بعد عمليات زراعة الأعضاء أو لعلاج أمراض المناعة الذاتية)؛<br />٦-مركابتوبورين أو ثيوغوانين (علاج كيميائي، يستخدم لعلاج سرطان الدم): -<br />- بعض الأدوية التي تمنع تجلط الدم(أدوية لمنع الجلطات ولزيادة سيولة الدم).</p><p><strong>الحمل، والرضاعة الطبيعية والخصوبة</strong><br />إذا كنت حاملاً أو ترضعين طفلك الرضاعة الطبيعية، أو تعتقدين أنك قد تكوني حاملاً أو تخططين لإنجاب طفل، اسألي<br />طبيبك أو الصيدلي للحصول على المشورة قبل أخذ هذا الدواء.<br />هناك تجربة محدودة مع استخدام ميسالازين أثناء الحمل والرضاعة الطبيعية. تم الإبلاغ عن اضطرابات الدم لدى المواليد<br />الجدد لأمهات تتم معالجتهن بهذا الدواء. وقد يصاب المولود الجديد بحساسية بعد الرضاعة من الثدي، على سبيل المثال<br />الإسهال. إذا أصيب المولود بإسهال، ينبغي وقف الرضاعة الطبيعية.</p><p><strong>القيادة واستخدام الآلات</strong></p><p>ليس من المعروف أن يؤثر هذا الدواء على القدرة على القيادة و/أو استخدام الآلات.</p><p><strong>ملاحظة: </strong>خطر الإصابة بسرطان القولون والمستقيم يزداد في حال التهاب القولون التقرحي، الآثار التي تم ملاحظتها من<br />الميسالازين في النماذج التجريبية وخزعات المرضى يدعم دور الميسالازين في الوقاية من سرطان القولون والمستقيم<br />المرتبط بالتهاب القولون، مع تثبيط الإشارات الناتجة عن الالتهاب أو غير الناتجة عن الالتهاب والمؤدية إلى نشوء<br />سرطان المستقيم والقولون المرتبط بالتهاب القولون.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول بنتاسا&nbsp;&reg; ١ غم أكياس&nbsp;دائماً كما أخبرك طبيبك تماماً، تحقق من طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p><u>البالغين:</u><br /><strong>لعلاج نوبات التهاب القولون التقرحي</strong>، سوف يصف لك طبيبك عادةً جرعة قد تصل إلى ٤غم ميسالازين (4-1 أكياس)&nbsp;مرة واحدة يومياً أو مقسمة على جرعات مفردة.<br /><strong>للمساعدة على الوقاية من الإصابة بنوبات أخرى</strong>، سوف يصف لك طبيبك عادةً ٢غم ميسالازين يومياً، تؤخذ كيس واحد&nbsp;بنتاسا&reg; اكستند ٢غم حبيبات بطيئة التحرر أو كيسان من بنتاسا&nbsp;&reg; ١ غم حبيبات بطيئة التحرر.</p><p><strong>الاستعمال في الأطفال والمراهقين</strong><br /><u>للأطفال من سن ٦ سنوات:</u><br />يتم تحديد الجرعة للأطفال من قبل الطبيب وتعتمد على وزن جسم الطفل. ينصح عادةً إعطاء الأطفال الذين يبلغ وزنهم<br />٤۰ كغم أو أقل نصف الجرعة التي تعطى للبالغين وأن تعطى جرعة البالغين الاعتيادية للأطفال الذين يزداد وزنهم عن<br />٤۰ كغم.&nbsp;</p><p><strong>يجب أن تأخذ الحبيبات عن طريق الفم، بعد فتح الكيس مباشرة كما هو موضح أدناه.</strong><br />لا تمضغ الحبيبات.<br />1. افتح الكيس.<br />2. أفرغ محتويات الكيس على اللسان.<br />3. ابلع الحبيبات مباشرة مع بعض الماء أو عصير البرتقال وتأكد من عدم بقاء أي حبيبات في الفم</p><p><strong>إذا أخذت جرعة بنتاسا&nbsp;&reg; ١ غم أكياس&nbsp;أكثر مما يجب:</strong></p><p>اتصل بطبيبك أو أقرب قسم للطوارئ على الفور.</p><p><strong>إذا نسيت أن تأخذ&nbsp; بنتاسا&nbsp;&reg; ١ غم أكياس</strong></p><p>إذا نسيت أن تأخذ جرعة، خذها حالما تتذكر ثم خذ الجرعة التالية في الوقت المعتاد. لا تأخذ جرعة مضاعفة لتعويض الجرعة المنسية.<br />إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية يمكن أن يتسبب هذا الدواء في آثار جانبية، بالرغم من أنها لا تحدث مع الجميع.كانت هناك تقارير قليلة جداً عن رد فعل تحسسي شديد )بما في ذلك تآكل شديد في الجلد الذي قد يؤثر على الجلد كحاجز<br />وقاية للجسم(. قد يؤدي رد الفعل التحسسي إلى تورم في الوجه والرقبة و / أو صعوبة في التنفس أو البلع )وذمة كوينكة<br />= وذمة وعائية عصبية(. إذا حدث ذلك اتصل بطبيبك أو أقرب قسم إصابات على الفور.</p><p><strong>الآثار الجانبية الشائعة</strong> التالية قد تؤثر على 1 من كل 10 أشخاص على الأكثر:<br />- الإسهال؛<br />- ألم في البطن؛<br />- الغثيان؛<br />- القيء؛<br />- صداع؛<br />- الطفح الجلدي؛<br />- انتفاخ البطن )خروج الريح(.<br /><strong>الآثار الجانبية النادرة</strong> التالية قد تؤثر على 1 من كل 1.000 شخص على الأكثر:<br />- التهاب في عضلة القلب أو غشاء القلب والذي يمكن أن يسبب ضيق في التنفس وألم في الصدر أو خفقان )ضربات<br />القلب السريعة أو غير المنتظمة(؛<br />- التهاب البنكرياس )تشمل أعراضه آلام الظهر و/أو المعدة(؛<br />- زيادة الأميليز )إنزيم يساعد على هضم الكربوهيدرات(؛<br />- الدوخة؛<br />- زيادة حساسية بشرتك لأشعة الشمس والأشعة فوق البنفسجية )حساسية للضوء(.<br /><strong>الآثار الجانبية النادرة جداً</strong> التالية قد تؤثر على 1 من كل 10 .000 شخص على الأكثر:<br />- فقر الدم واضطرابات الدم الأخرى )نقص في أعداد خلايا معينة في الدم، الذي يمكن أن يسبب نزيف غير مبرر،<br />كدمات، حمى أو التهاب الحلق(؛<br />- اضطرابات الكبد )تشمل الأعراض اليرقان )اصفرار الجلد أو العينين( و/أو شحوب لون البراز(؛<br />- اضطرابات في الكلى )تشمل الأعراض الدم في البول، و / أو التورم بسبب تراكم السوائل(؛<br />- اعتلالات الأعصاب الطرفية )حالة تؤثر على أعصاب اليدين والقدمين، وتشمل الأعراض وخز وخدران(؛<br />- ردود فعل تحسسية وزيادة النسيج الضام )تليّف( في الرئة، والتهاب في بطانة الرئتين أو تندب الرئة )تشمل<br />الأعراض السعال، تقلص الشعب الهوائية )التشنج القصبي(، وعدم الراحة في الصدر أو ألم مع التنفس، وصعوبات<br />في التنفس، وظهور دم بالبلغم أو زيادة إنتاج البلغم(؛<br />- التهاب الأمعاء التقرحي الشامل )نوع من اضطرابات الأمعاء الالتهابية التي تؤثر على البطانة الداخلية الكاملة<br />للأمعاء الكبيرة(؛<br />- فقدان الشعر المؤقت؛<br />- آلام العضلات أو المفاصل؛<br />- الالتهاب الذي يمكن أن يؤثر على أجزاء مختلفة من الجسم مثل المفاصل والجلد والكلى والقلب وما إلى<br />ذلك )وتشمل الأعراض آلام المفاصل والتعب والحمى ونزيف غير طبيعي أو غير مبرر مثل )نزيف<br />الأنف(، وكدمات، ظهور لون أرجواني على الجلد، ظهور البقع تحت الجلد )بما في ذلك تقرحات الجلد<br />الشديدة والتلف الحاد الذي قد يؤثر على الجلد كحاجز واقي للجسم(؛<br />- تراكم السوائل في كيس القلب )انصباب التأمور( والتي يمكن أن تسبب ألم أو ضغط في الصدر؛<br />- تغير في لون البول؛<br />- تركيز منخفض للحيوانات المنوية في السائل المنوي (قلة النطاف))مؤقت(؛<br />- إسهال شديد وآلام في البطن بسبب رد فعل تحسسي لهذا الدواء داخل الأمعاء؛<br />- قد تحدث ردود فعل الحساسية والحمى أحياناً.<br />وردت تقارير قليلة جداً عن حدوث ارتفاع ضغط الدم الحميد داخل الجمجمة )تراكم السوائل حول المخ( لدى<br />المراهقين. وتشمل الأعراض الصداع والغثيان والقيء واضطرابات بصرية و/أو سمعية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب الحفاظ على هذا الدواء بعيداً عن متناول ونظر الأطفال.<br />يحفظ في درجة حرارة الغرفة )أقل من ٢٥ درجة مئوية( في العبوة الأصلية بعيداً عن الضوء.<br />لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العلبة الخارجية وعلى الكيس القصدير. يشير<br />تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر المذكور.<br />لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من<br />الأدوية التي لم تعد تستخدم. سوف تساعد هذه التدابير في حماية البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><u>لمادة الفعالة هي الميسالازين:</u> يحتوي كل كيس بنتاسا &reg; ١ غم أكياس&nbsp;حبيبات بطيئة التحرر على ١ غم ميسالازين.</p><p><u>المكونات الأخرى هي:</u> ايثيل سيليلوز، وبوفيدون.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            هذا الدواء يحتوي على حبيبات بطيئة التحرر. الحبيبات بيضاء‑رمادية إلى بيضاء‑بنية فاتحة اللون.
يتوفر بنتاسا ® ١ غم أكياس في أكياس المنيوم في عبوات تحتوي على 50 كيس.
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>المصنع</strong><br />فيرينغ انترناشونال سنتر اس اي، شومان دي لا فيروغوغنوزاز&nbsp; 1162,50&nbsp;سانت بريكس، سويسرا.<br /><strong>مالك حق التسويق</strong><br />فيرينغ جي ام بي اتش، ويتلاند ١١ ، د - ٢٤ ١٠٩ كييل، ألمانيا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            حزيران 2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                PENTASA Sachet 1000 mg prolonged release granules
Mesalazine
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each sachet PENTASA Sachet 1000 mg prolonged release granules contains 1 g mesalazine.
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Prolonged release granules
White-grey to pale white-brown granules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mild to moderate ulcerative colitis</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology<br />Ulcerative colitis:<br /><strong>Adults</strong></u><br />Active disease:<br />Individual dosage, up to 4 g mesalazine once daily or divided into 2-4 doses.<br />Maintenance treatment:<br />Individual dosage. Recommended dosage, 2 g mesalazine once daily.<br /><strong><u>Paediatric population</u></strong><br />The safety and efficacy in children below 6 years of age have not been established.<br />There is only limited documentation for an effect in children (age 6-18 years).<br /><u>Children 6 years of age and older:</u><br />Active disease:<br />To be determined individually, starting with 30&ndash;50 mg/kg /day in divided doses.<br />Maximum dose: 75 mg/kg/day in divided doses. The total dose should not exceed 4 g/day (maximum adult dose).<br />Maintenance treatment:<br />To be determined individually, starting with 15-30 mg/kg/day in divided doses. The total dose should not exceed<br />2 g/day (recommended adult dose).<br />It is generally recommended that half the adult dose may be given to children up to a body weight of 40 kg; and<br />the normal adult dose to those above 40 kg.<br /><u>Method of administration</u><br />Oral use.<br />The granules must not be chewed. The contents of the sachet should be emptied onto the tongue and washed<br />down with some water or orange juice.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to mesalazine, any of the excipients listed in section 6.1 or salicylates. Severe liver and/or renal
impairment
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Caution is recommended when treating patients allergic to sulphasalazine (risk of allergy to salicylates). In case<br />of acute symptoms of intolerance, i.e. abdominal cramps, abdominal pain, fever, severe headache and rash, the<br />treatment should be discontinued immediately.<br />Caution is recommended in patients with impaired liver function. Liver function parameters like ALT or AST<br />should be assessed prior to and during treatment, at the discretion of the treating physician.<br />The drug is not recommended for use in patients with impaired renal function and in patients with haemorrhagic<br />diathesis. The renal function should be regularly monitored (e.g. serum creatinine), especially during the initial<br />phase of treatment. Urinary status (dip sticks) should be determined prior to and during treatment at the<br />discretion of the treating physician. Mesalazine induced nephrotoxicity should be suspected in patients<br />developing renal dysfunction during treatment. The concurrent use of other known nephrotoxic agents, such as<br />NSAIDs and azathioprine, may increase the risk of renal reactions.<br />Caution is recommended in patients with active peptic ulcer.<br />Patients with pulmonary disease, in particular asthma, should be very carefully monitored during a course of<br />treatment; see section 4.8.<br />Mesalazine-induced cardiac hypersensitivity reactions (myo- and pericarditis) have been reported rarely. Serious<br />blood dyscrasias have been reported very rarely with mesalazine (see section 4.5). Blood tests for differential<br />blood counts is recommended prior to and during treatment, at the discretion of the treating physician. Treatment<br />should be discontinued on suspicion or evidence of these adverse reactions.<br />As a guideline, follow-up tests are recommended 14 days after commencement of treatment, then a further two to<br />three tests at intervals of 4 weeks. If the findings are normal, follow-up tests should be carried out every three<br />months. If additional symptoms occur, these tests should be performed immediately.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed. Combination therapy with mesalazine and azathioprine or 6-<br />mercaptopurine or thioguanine has shown a higher frequency of myelosuppressive effects. An interaction cannot<br />be excluded, however, the mechanism of interaction is unknown. Regular monitoring of white blood cells is<br />recommended and dosage of thiopurines should be adjusted accordingly.<br />There is weak evidence that mesalazine might decrease the anticoagulant effect of warfarin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PENTASA prolonged release granules should not be used during pregnancy and lactation except when the<br />potential benefits of the treatment outweigh the possible hazards in the opinion of the physician. The underlying<br />condition itself (Inflammatory bowel disease (IBD)) may increase risks for adverse pregnancy outcome.<br />Pregnancy:<br />Mesalazine is known to cross the placental barrier and its concentration in umbilical cord plasma is lower than<br />the concentration in maternal plasma. The metabolite acetyl-mesalazine is found at similar concentrations in<br />umbilical cord and maternal plasma. Animal studies on oral mesalazine do not indicate direct or indirect harmful<br />effects with respect to pregnancy, embryo/foetal development, parturition or postnatal development. There are no<br />adequate and well controlled studies of PENTASA use in pregnant women. Limited published human data on<br />mesalazine show no increase in the overall rate of congenital malformations. Some data show an increased rate of<br />preterm birth, stillbirth, and low birth weight; however, these adverse pregnancy outcomes are also associated<br />with active inflammatory bowel disease. Blood disorders (leucopenia, thrombocytopenia and anaemia) have been<br />reported in new-borns of mothers being treated with PENTASA prolonged release granules.<br />In one single case after long-term use of a high dose of mesalazine (2-4g, orally) during pregnancy, renal failure<br />in a neonate was reported.<br />Lactation:<br />Mesalazine is excreted in breast milk. The mesalazine concentration in breast milk is lower than in maternal<br />blood, whereas the metabolite - acetyl-mesalazine - appears in similar or increased concentrations. No controlled</p><p>studies with PENTASA prolonged release granules during breast-feeding have been carried out. Only limited<br />experience during lactation in women after oral application is available to date.<br />Hypersensitivity reactions like diarrhea in the infant cannot be excluded. If the infant develops diarrhoea, breastfeeding<br />should be discontinued.<br />Fertility:<br />Animal data on Mesalazine show no effect on male and female fertility</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PENTASA prolonged release granules has no or negligible influence on the ability to drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most frequent adverse reactions seen in clinical trials are diarrhoea, nausea, abdominal pain, headache,<br />vomiting, and rash.<br />Hypersensitivity reactions and drug fever may occasionally occur.<br />Frequency of adverse effects, based on clinical trials and reports from post-marketing surveillance:</p><table style="width:1011px" border="1" cellspacing="1" cellpadding="1"><tbody><tr><td style="width:198px">Very rare:<br />(&lt; 1/10,000)</td><td style="width:237px">Rare<br />(&ge;1/10,000 to<br />&lt;1/1,000)</td><td style="width:298px">Common<br />(&ge; 1/100 to &lt;1/10)</td><td style="width:275px">System organ<br />class</td></tr><tr><td style="width:198px">Altered blood counts [Anaemia,<br />aplastic anaemia,<br />agranulocytosis, neutropenia,<br />leukopenia (incl.<br />granulocytopenia), pancytopenia,<br />thrombocytopenia, and<br />eosinophilia (as part of an<br />allergic reaction)].</td><td style="width:237px">&nbsp;</td><td style="width:298px">&nbsp;</td><td style="width:275px">Blood and<br />lymphatic system<br />disorders</td></tr><tr><td style="width:198px">Hypersensitivity reaction<br />including anaphylactic reaction,<br />Drug Reaction with Eosinophilia<br />and Systemic Symptoms<br />(DRESS)</td><td style="width:237px">&nbsp;</td><td style="width:298px">&nbsp;</td><td style="width:275px">Immune system<br />disorders</td></tr><tr><td style="width:198px"><p>Peripheral neuropathy</p><p><br />Benign intracranial hypertension<br />in adolescents</p></td><td style="width:237px">Dizziness</td><td style="width:298px">Headache</td><td style="width:275px">Nervous system<br />disorders</td></tr><tr><td style="width:198px">Pericardial effusion</td><td style="width:237px"><p>Myocarditis*</p><p><br />Pericarditis*</p></td><td style="width:298px">&nbsp;</td><td style="width:275px">Cardiac disorders</td></tr><tr><td style="width:198px">Allergic alveolitis, allergic and<br />fibrotic lung reactions (incl.<br />dyspnoea, coughing,<br />bronchospasm, pulmonary<br />eosinophilia, interstitial lung<br />disease, pulmonary infiltration,<br />pneumonitis)</td><td style="width:237px">&nbsp;</td><td style="width:298px">&nbsp;</td><td style="width:275px">Respiratory,<br />thoracic and<br />mediastinal<br />disorders</td></tr><tr><td style="width:198px">Pancolitis</td><td style="width:237px"><p>Acute Pancreatitis*</p><p>Increased amylase<br />values (blood and/or<br />urine)</p></td><td style="width:298px">Diarrhoea<br />Abdominal pain<br />Nausea<br />Vomiting<br />Flatulence</td><td style="width:275px">Gastrointestinal<br />disorders</td></tr><tr><td style="width:198px">Increased liver enzymes,<br />cholestasis parameters and<br />bilirubin, hepatotoxicity (incl.<br />hepatitis*, cholestatic hepatitis,<br />cirrhosis, hepatic<br />failure)</td><td style="width:237px">&nbsp;</td><td style="width:298px">&nbsp;</td><td style="width:275px">Hepato-biliary<br />disorders</td></tr><tr><td style="width:198px">Reversible alopecia, Quincke&rsquo;s<br />oedema, Dermatitis allergic,<br />Erythema multiforme Stevens-<br />Johnson Syndrome (SJS)</td><td style="width:237px">Photosensitivity**</td><td style="width:298px">Rash (incl. urticaria,<br />erythematous rash)</td><td style="width:275px">Skin and<br />subcutaneous tissue<br />disorders</td></tr><tr><td style="width:198px">Myalgia<br />Arthralgia<br />lupus erythematosus-like<br />reactions</td><td style="width:237px">&nbsp;</td><td style="width:298px">&nbsp;</td><td style="width:275px">Musculoskeletal,<br />connective tissue<br />and bone disorders</td></tr><tr><td style="width:198px"><p>Renal impairment (incl.<br />acute/chronic interstitial<br />nephritis*, nephrotic syndrome,<br />(acute/chronic) renal<br />insufficiency)</p><p>,<br />urine discolouration</p></td><td style="width:237px">&nbsp;</td><td style="width:298px">&nbsp;</td><td style="width:275px">Renal and urinary<br />disorders</td></tr><tr><td style="width:198px">Oligospermia (reversible)</td><td style="width:237px">&nbsp;</td><td style="width:298px">&nbsp;</td><td style="width:275px">Reproductive<br />system disorders</td></tr><tr><td style="width:198px">Drug fever</td><td style="width:237px">&nbsp;</td><td style="width:298px">&nbsp;</td><td style="width:275px">General disorders<br />and administration<br />site conditions</td></tr></tbody></table><p>(*)</p><p>The mechanism of mesalazine-induced myo- and pericarditis, pancreatitis, nephritis and hepatitis is unknown,<br />but it might be of allergic origin.<br />(**) Photosensitivity: More severe reactions are reported in patients with pre-existing skin conditions such as<br />atopic dermatitis and atopic eczema.<br />It is important to note that several of these disorders can also be attributed to the inflammatory bowel disease<br />itself.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Experience in animals:</u> A single intravenous dose of mesalazine in rats of 920 mg/kg and single oral doses of<br />mesalazine in pigs up to 5 g/kg were not lethal.<br /><u>Human experience: </u>There is limited clinical experience with overdose of PENTASA prolonged release granules<br />which does not indicate renal or hepatic toxicity. Since PENTASA is an amino salicylate, symptoms of salicylate<br />toxicity may occur. Symptoms of salicylate over dosage are well described in the literature.<br />There have been reports of patients taking daily oral doses of 8 g for a month without any adverse events</p><p>There is no specific antidote and treatment is symptomatic and supportive. The treatment at hospital includes<br />close monitoring of renal function</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Intestinal anti-inflammatory agents, aminosalicylic acid and similar agents<br />ATC code: A07E C02<br />Mesalazine is the active component of sulfasalazine, which has been used for a long time in the treatment of<br />ulcerative colitis and Crohn&rsquo;s disease.<br />The therapeutic value of mesalazine appears to be due to local effect on the inflamed intestinal tissue, rather than<br />to systemic effect.<br />There is information suggesting that severity of colonic inflammation in ulcerative colitis patients treated with<br />mesalazine is inversely correlated with mucosal concentrations of mesalazine.<br />Increased leukocyte migration, abnormal cytokine production, increased production of arachidonic acid<br />metabolites, particularly leukotriene B4, and increased free radical formation in the inflamed intestinal tissue are<br />all present in patients with inflammatory bowel disease. The mechanism of action of mesalazine is not fully<br />understood although mechanisms such as activation of the &gamma;-form of peroxisome proliferator-activated receptors<br />(PPAR-&gamma;) and inhibition of nuclear factor-kappa B (NF-&kappa;B) in the intestinal mucosa have been implicated.<br />Mesalazine has in-vitro and in-vivo pharmacological effects that inhibit leukocyte chemotaxis, decrease cytokine<br />and leukotriene production and scavenge for free radicals. It is currently unknown which, if any, of these<br />mechanisms play a predominant role in the clinical efficacy of mesalazine.<br />The risk of colorectal cancer (CRC) is slightly increased in ulcerative colitis.<br />Observed effects of mesalazine in experimental models and patient biopsies support the role of mesalazine in<br />prevention of colitis-associated CRC, with down regulation of both inflammation dependent and noninflammation<br />dependent signalling pathways involved in the development of colitis-associated CRC. However<br />data from meta-analyses, including both referral and non-referral populations, provide inconsistent clinical<br />information regarding the benefit of mesalazine in the carcinogenesis risk associated with ulcerative colitis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>General characteristics of the active substance</strong><br />Disposition and local availability:<br />The therapeutic activity of mesalazine most likely depends on a local contact of the drug with the diseased area<br />of the intestinal mucosa.<br />PENTASA prolonged release granules consist of ethylcellulose coated microgranules of mesalazine. The coated<br />microgranules enter the duodenum within an hour of administration, independent of food co-administration.<br />Mesalazine is continuously released from the coated microgranules throughout the gastrointestinal tract in any<br />enteral pH conditions.<br />Absorption: Bioavailability of PENTASA after oral administration can be estimated to approx. 30%, based on<br />urine recovery data in healthy volunteers. Maximum plasma concentrations are seen 1-6 hours post-dose. A oncedaily<br />dosing regimen of mesalazine (1 &times; 4 g/d) and a twice-daily dosage (2 &times; 2 g/d) results in a comparable<br />systemic exposure (AUC) over 24 hours and indicate a continuous release of mesalazine from the formulation<br />over the treatment period. Steady-state is reached after a treatment period of 5 days following oral administration.</p><p><img width="858" height="200" alt="" src="data:image/png;base64,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" /></p><p>The transit and release of mesalazine after oral administration are independent of food co-administration,<br />whereas the systemic exposure may be increased.</p><p><u>Distribution</u>: Mesalazine and acetyl-mesalazine do not cross the blood-brain barrier. Protein binding of<br />mesalazine is approximately 50% and of acetyl-mesalazine about 80%.<br /><u>Metabolism</u>: Mesalazine is metabolised both pre-systemically by the intestinal mucosa and systemically in the<br />liver to N-acetyl-mesalazine (acetyl-mesalazine) principally by NAT-1. Some acetylation also occurs through the<br />action of colonic bacteria. The acetylation seems to be independent of the acetylator phenotype of the patient.<br />The metabolic ratio of acetyl-mesalazine to mesalazine in plasma after oral administration ranges from 3.5 to 1.3<br />after daily doses of 500 mg x 3 and 2 g x 3, respectively, implying a dose-dependent acetylation which may be<br />subject to saturation.<br /><u>Elimination</u>: Due to the continuous release of mesalazine throughout the gastrointestinal tract, the elimination<br />half-life cannot be determined after oral administration.<br />However, once the formulation is not present in the GI tract elimination will follow the plasma half-life of orally<br />or iv administered uncoated mesalazine, which is approximately 40 minutes and for acetyl-mesalazine<br />approximately 70 minutes.<br /><strong>Characteristics in patients</strong><br />Pathophysiologic changes such as diarrhoea and increased bowel acidity observed during active inflammatory<br />bowel disease have only a minor impact on the delivery of mesalazine to the intestinal mucosa after oral<br />administration. A urine excretion 20-25% of the daily dose has been observed in patients with accelerated<br />intestinal transit. Likewise, a corresponding increase in faecal excretion has been seen.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Toxic renal effects have been demonstrated in all species tested. Rat and monkey dosages and plasma<br />concentrations at the No Observed Adverse Effect Levels (NOAELs) exceed those used in humans by a factor of<br />2-7.2.<br />In vitro test systems and in-vivo studies showed no evidence of mutagenic effects. Studies on the tumourigenic<br />potential carried out in rats showed no evidence of any substance-related increase in the incidence of tumours.<br />Animal studies on oral mesalazine do not indicate direct or indirect harmful effects with respect to fertility,<br />pregnancy, embryo-foetal development, parturition or postnatal development.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ethylcellulose<br />Povidone</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
The granules should be used immediately after first opening of the sachet.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product does not require any special storage conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Polyester/Aluminium/LD polyethylene sachet.<br />Pack size:<br />1 x 50 sachets</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                FERRING GmbH
Wittland 11
D-24109 Kiel
Germany
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                June 2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>